METHYL {(2S,3R)-1-(2S)-2-{5-(2R,5R)-1-{3,5-DIFLUORO-4-4-(4-FLUOROPHENYL)PIPERIDIN-1-YLPHENYL}-5-(6-FLUORO-2-{(2S)-1-N-(METHOXYCARBONYL)-O-METHYL-L-THREONYLPYRROLIDIN-2-yl}-1H-BENZIMIDAZOL-5-YL)PYRROLIDIN-2-YL-6-FLUORO-1H-BENZIMIDAZOL-2-YL}PYRROLIDIN-1-YL-3-METHOXY-1-OXOBUTAN-2-YL}CARBAMATE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD OF TREATING HCV INFECTION

摘要

A compound, in particular methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1H-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate, or a pharmaceutically acceptable salt thereof, effective in inhibiting replication of Hepatitis C virus (HCV) is described. This invention also relates to a pharmaceutical composition comprising such compound, and to a method of treating HCV infection.